Journal of Headache and Pain

Papers
(The H4-Index of Journal of Headache and Pain is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study324
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine138
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis110
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache85
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency77
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation71
Debate: Are cluster headache and migraine distinct headache disorders?65
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study60
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks60
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia56
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China48
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine47
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine43
Measuring interictal burden among people affected by migraine: a descriptive survey study42
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results41
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients41
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI38
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury37
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey35
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States34
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study33
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study32
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study32
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting32
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain31
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study30
Development and validation of a novel model for characterizing migraine outcomes within real-world data29
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients29
0.074244976043701